Journal
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
Volume 18, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/ijerph18041941
Keywords
pharmacovigilance; medicine safety; Neglected Tropical Diseases Program; public health program; East Africa
Funding
- European and Developing Countries Clinical Trials Partnership (EDCTP) 2 program - European Union [CSA2016S-1618]
- Swedish International Development Cooperation Agency (SIDA)
Ask authors/readers for more resources
The pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania were assessed using the East African Community Harmonized Pharmacovigilance Indicators tool. Despite having strategic master plans with pharmacovigilance components, limited or no individual case safety reports were received, and there was minimal collaboration with national pharmacovigilance centers. These programs lacked a specific budget for pharmacovigilance, and although some safety monitoring elements were present, key elements such as adverse event reporting and collaboration with national centers were limited or missing.
Monitoring the safety of medicines used in public health programs (PHPs), including the neglected tropical diseases (NTD) program, is a WHO recommendation, and requires a well-established and robust pharmacovigilance system. The objective of this study was to assess the pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania. The East African Community Harmonized Pharmacovigilance Indicators tool for PHPs was used to interview the staff of the national NTD programs. Data on four components, (i) systems, structures, and stakeholder coordination; (ii) data management and signal generation; (iii) risk assessment and evaluation; and (iv) risk management and communication, were collected and analyzed. The NTD programs in the four countries had a strategic master plan, with pharmacovigilance components and mechanisms to disseminate pharmacovigilance information. However, zero individual case safety reports were received in the last 12 months (2017/2018). There was either limited or no collaboration between the NTD programs and their respective national pharmacovigilance centers. None of the NTD programs had a specific budget for pharmacovigilance. The NTD program in all four countries had some safety monitoring elements. However, key elements, such as the reporting of adverse events, collaboration with national pharmacovigilance centers, and budget for pharmacovigilance activity, were limited/missing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available